Filing Flows › Industrials › Foxo Technologies (FOXO)
Foxo Technologies (FOXO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Foxo Technologies (FOXO) Q2 2026 earnings results →
Q2 2026 Revenue down 10% year over year to $4.7M · 173¢ of every $1 of revenue kept as net profit · operating margin 185.5%
Foxo Technologies made $4.7M in Q2 2026 (-10% Y/Y): Health Cares $4.5M, Life Science Services $238K, Labs $6K. Operating margin 185.5%, net earnings $8.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $4.7M in Q2 2026, down 10% year over year and down 9% from the previous quarter. Health Cares was the largest line at 95% of revenue. Health Cares lost $740K year over year (down 14%), 147% of the total change.
Operating profit was $8.7M, a 185.5% margin (up 174.7 points year over year). Net earnings were $8.1M. The effective tax rate was 0.0%.
Operating cash flow was $299K, 4% of net earnings. Non-cash charges added back $176K of depreciation and amortization. Working capital and other items used $8.0M. Capital expenditures of $5K left free cash flow of $293K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $4.7M | -10% | 185.5% | $8.1M | $299K |
| Q1 2026 | 10-Q | May 15, 2026 | $5.2M | +63% | -5.4% | −$1.5M | −$578K |
| Q4 2025 | 10-K | Apr 15, 2026 | $4.4M | +57% | -191.6% | −$9.4M | −$104K |
| Q3 2025 | 10-Q | Nov 10, 2025 | $3.5M | +196% | -24.2% | −$1.9M | −$45K |
| Q2 2025 | 10-Q | Aug 19, 2025 | $5.2M | 190× | 10.9% | −$526K | −$2.4M |
| Q1 2025 | 10-Q | May 20, 2025 | $3.2M | 441× | -48.8% | −$621K | −$1.3M |
| Q4 2024 | 10-K | Apr 15, 2025 | $2.8M | 26× | -141.4% | −$6.8M | −$1.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Foxo Technologies
FOXO Technologies Inc., is a healthcare services and technology company. We currently operate four synergistic divisions: (i) a rural hospital division; (ii) a mental and behavioral health division; (iii) an information, data and biospecimen sourcing division; and (iv) an epigenetics diagnostics and interpretation division. Our mission is to build healthier communities by encompassing technology and expertise to offer a diverse and adaptable range of healthcare services and solutions to improve the quality of healthcare and lives for those we serve.
In its own words, from its 10-K, filed Apr 15, 2026.
Foxo Technologies against its Services-Commercial Physical & Biological Research peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -10% against the peers' median +8%. Operating margin: 185.5% against the peers' median 12.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| FOXO Foxo Technologies | Q2 2026 | $4.7M | -10% | 185.5% |
| IQV IQVIA Holdings | Q3 2026 | $4.4B | +8% | 12.9% |
| INCY Incyte | Q3 2026 | $1.6B | +14% | -45.5% |
| CRL Charles River Laboratories International | Q3 2026 | $983M | -2% | 20.6% |
| MEDP Medpace Holdings | Q3 2026 | $716M | +8% | 23.1% |
| NRC NRC Health | Q3 2026 | $38.4M | +11% | 23.2% |
| MXCT Maxcyte | Q2 2026 | $7.3M | -14% | -140.7% |
| OABI OmniAb | Q3 2026 | $4.0M | +78% | -409.9% |
| BIAF bioAffinity Technologies | Q3 2026 | $1.1M | -26% | -328.0% |
Source: Foxo Technologies 10-Q on SEC EDGAR · CIK 1812360 · Services-Commercial Physical & Biological Research
More on FOXO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results